PET/CT imaging of PD-1 receptor probe targeting S180 sarcoma in mice
10.19405/j.cnki.issn1000–1492.2026.04.012
- VernacularTitle:靶向小鼠S180肉瘤PD-1受体探针的PET/CT显像研究
- Author:
Haifeng HUANG
1
;
Jiangnan SUN
2
;
Huan ZOU
3
;
Tao BAO
2
;
Hua ZHU
4
;
Xianteng YANG
1
;
Shanshan LI
5
Author Information
1. Dept of Orthopaedics， 5Dept of Anesthesiology， Guizhou Provincial People’s Hospital， Guiyang 550002
2. The First Clinical Medical College， Zunyi Medical University， Zunyi 563000
3. Dept of Rehabilitation， Guizhou Provincial Staff Hospital， Guiyang 550025
4. Key Laboratory for Research and Evaluation ofRadiopharmaceuticals （National Medical Products Administration）， Key Laboratory of Carcinogenesis and Translational Research， Ministry of Education （Beijing）， Department of Nuclear Medicine， Peking University Cancer Hospital & Institute， Beijing 100142
5. Dept of Anesthesiology， Guizhou Provincial People’s Hospital， Guiyang 550002，
- Publication Type:Journal Article
- Keywords:
fullerene C60;
lung tumor;
N-bis （2-hydroxypropyl） nitrosamine;
intratracheal spraying;
Fisher 344 rats
- From:
Acta Universitatis Medicinalis Anhui
2026;61(4):682-688
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo explore the feasibility of constructing a programmed death receptor-1（PD-1） molecular probe for non-invasive micro-positron emission tomography/computed tomography （Micro-PET/CT） imaging of PD-1 protein in mouse S180 sarcoma. MethodsA transgenic PD-1 C57 S180 sarcoma mouse model was established using the S180 sarcoma cell injection. Furthermore， 124I-anti-PD-1 monoclonal antibody probe was synthesized. 18.5 MBq of the 124I-anti-PD-1 probe was injected into the tail vein of transgenic PD-1 C57 mice. Subsequently， S180 sarcoma was imaged using Micro-PET/CT. ResultsStudy successfully established a transgenic PD-1 C57 S180 sarcoma mouse model. Immunohistochemical （IHC） results showed PD-1 protein expression in S180 sarcoma. Micro-PET/CT imaging successfully visualized the PD-1 protein receptor in S180 sarcoma at different time points （20， 48， 72， and 120 h） after probe injection. ConclusionThe 124I-anti-PD-1 monoclonal antibody molecular probe successfully targets the PD-1 receptor in S180 sarcoma of transgenic PD-1 C57 mice， and presents clear Micro-PET/CT immunoassay results， thus it potentially enables the non-invasive screening of patients with PD-1 positive malignant tumors.
